suPARnostic® news

NEW STUDY Soluble urokinase-type plasminogen activator receptor improves early risk stratification in cardiogenic shock Conclusion SuPAR associates with mortality and improves risk stratification independently of other previously known risk factors in CS patients. Aims Soluble [...]

NEW STUDY Soluble urokinase plasminogen activator receptor and decline in kidney function among patients without kidney disease Conclusion A higher suPAR level was associated with accelerated eGFR decline among patients presenting to the emergency [...]

NEW STUDY suPAR: An Inflammatory Mediator for Kidneys Conclusion The last 10 years of research has established suPAR as a unique inflammatory mediator for kidneys. While open questions remain and deserve additional studies, modulating [...]

NEW STUDY Soluble urokinase Plasminogen Activator Receptor (suPAR) levels are predictive of COVID-19 severity: an Italian experience Conclusion suPAR levels correlate with disease severity and survival rate of COVID-19 patients, representing a promising prognostic [...]

NEW STUDY Soluble Urokinase Plasminogen Activator Receptor and Venous Thromboembolism in COVID‐19 Conclusion Higher suPAR was associated with incident venous thromboembolism (VTE) independently of D‐dimer in patients hospitalized for COVID‐19. Combining suPAR and D‐dimer [...]

NEW STUDY suPAR in the Emergency Department: A Tool for the Assessment of Elderly Patients Conclusion The study results suggest that suPAR levels were clearly elevated in the ED patients, the elderly patients displaying [...]

NEW STUDY Circulating suPAR associates with severity and in-hospital progression of COVID-19 BACKGROUND: COVID-19 disease progression is characterized by hyper inflammation, and risk stratification may aid in early aggressive treatment and advanced planning. The aim [...]